Database

Startups

Main Industry
Biotechnology
Main Product/Service
ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immun
Founded Year
2022
Unified Business No.
90379709
Status
Active
Number of Employees
15
Total Paid-in Capital
373,600,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
Dedicated to enhancing human health and well-being, ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. Our team members have accumulated years of experience in medicinal chemistry, dru



More ↓

Similar Companies

ChemAI Co., Ltd.

Solutions -
1. ADDD platform
2. VIRTUALMAN for ADMET/PK
3. Customized Al

Insilico Medicine Taiwan Limited

Insilico’s flagship suite includes PandaOmics (multi-omics target identification), Chemistry42 (de novo molecular design), and InClinico (clinical outcome prediction). By leveraging these AI modules, they can rapidly generate novel molecules, predict safe